Amyloid PET in the diagnostic workup of neurodegenerative disease

Pierpaolo Alongi, Agostino Chiaravalloti, Valentina Berti, Cecilia Vellani, Giuseppe Trifirò, Giulia Puccini, Giulia Carli, Andrea Chincarini, Silvia Morbelli, Daniela Perani, Stelvio Sestini

Research output: Contribution to journalArticlepeer-review


Several radiotracers have been employed to bind amyloid plaques in the brain for the differential diagnosis of neurodegenerative disease, open the possibility to measure in vivo pathogenic processes implicated in Alzheimer disease (AD) and have the potential to detect disease processes at the earliest stages with a potential role in clinical trials’ longitudinal assessment. Visual reading is clinically adequate in clearly positive or negative cases but the adoption of validated and standardized quantification methods of amyloid-PET to diagnose AD in research and clinical settings has become essential. The present Pictorial Essay presenting a case series of nine patients describes the current role of amy-PET imaging elucidating the typical assessment, the possible artifacts and pitfalls occurring in the clinical scenario, focusing also on the development of quantification methods in the diagnostic workup of neurodegenerative disease.

Original languageEnglish
Pages (from-to)383-397
JournalClinical and Translational Imaging
Publication statusPublished - 2021


  • 18F-Florbetaben
  • 18F-Florbetapir
  • 18F-Flutemetamol
  • Alzheimer’s disease
  • Amyloid PET
  • Positron emission tomography computed tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Amyloid PET in the diagnostic workup of neurodegenerative disease'. Together they form a unique fingerprint.

Cite this